TCR CO-STIM
Alternative Names: TCR:CO-STIMLatest Information Update: 05 Aug 2024
At a glance
- Originator Pan Cancer T
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Malignant melanoma; Triple negative breast cancer